Resistance to activated protein C is a risk factor for fibrostenosis in Crohn’s disease

Table 1 Characteristics of 32 patients with Crohn's disease (frequencies, %, median values with range)

	With aPCR	Without aPCR
	(n = 8)	(n = 24)
Sex ratio (M/F)	3/5	9/15
Age at diagnosis (yr)	30 (13-53)	31 (10-46)
Duration of disease (mo)	140 (86-257)	145 (65-272)
aPC ratio1	1.52 (1.19-1.64)	2.31 (2.08-2.66)
Patients with VTE in the history	5 (63%)b	2 (8%)
Smokers	4 (50%)	19 (79%)
Patients under azathioprine	4 (50%)	15 (63%)
Location of CD2
Terminal ileum	2 (25%)	4 (17%)
Colon	1 (12.5%)	5 (21%)
Ileocolon	4 (50%)	12 (50%)
Upper gastrointestinal tract	1 (12.5%)	3 (12%)

aPCR: resistance to activated protein C; CD: Crohn’s disease; VTE: venous thromboembolism.

¹The patients were divided into the two groups according to the value of the aPC ratio: ≤ (diagnosis of aPCR) and > 1.9 (normal range), respectively.

²The location of disease was classified according to the Vienna classification[26].

^bP < 0.01 vs patients without aPCR.

Table 2 Intestinal CD-related surgery in 32 patients with Crohn's disease (frequencies, %, median values)

	With aPCR	Without aPCR
	(n = 8)	(n = 24)
Patients having undergone an operation1	6 (75%)	16 (67%)
Patients having undergone an operation with fibrostenosis2	6 (75%)	13 (54%)
Patients with fibrostenosis at 1st operation2	6/6 (100%)	10/16 (62.5%)
Location of fibrostenosis at 1st operation3
Terminal ileum	4	8
Colon	2	0
Upper gastrointestinal tract	0	2
Median time from diagnosis of CD to 1st operation1 (mo)	32	80.5
Median time from diagnosis of CD to 1st operation with fibrostenosis2 (mo)	32a	160

aPCR: resistance to activated protein C; CD: Crohn’s disease.

¹Operations:intestinal CD-related operations;

²Operations with fibrostenosis: intestinal CD-related operations with fibrostenosis;

³The location of fibrostenosis was classified according to the Vienna classification for location of Crohn’s disease[26].

^aP < 0.05 vs patients without aPCR.